HONG KONG – Commercial-stage biotech company Beigene Ltd. and clinical-stage company Bioatla LLC agreed to co-develop and bring to the market BA-3071, an investigational conditionally active biologic (CAB) CTLA4 antibody, as a monotherapy and in combination with Beigene's investigational anti-PD-1 antibody, tislelizumab, to treat cancer.